Compare Ascendis Pharma A/S (ASND) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Kinder Morgan Inc — how do they compare? Ascendis Pharma A/S trades at $256.59 (market cap $16.67B), while Kinder Morgan Inc trades at $31.72 (market cap $70.10B). The key difference: Kinder Morgan Inc is far larger — about 4.2× Ascendis Pharma A/S's market cap, and Kinder Morgan Inc pays a 3.75% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | KMI | |
|---|---|---|
Market Cap | $16.67B | $70.10B |
Sector | Health | Energy |
52-Week High | $277.18 | $34.31 |
52-Week Low | $189.74 | $25.84 |
Enterprise Value | $17.04B | $102.15B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
KMI trades at $31.76, up 1.16% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates, and raised full-year guidance. Revenue grew to $16.94B in 2025, with net income margin expanding to 19.31%. Recent news highlights a $5 billion Western Gateway Pipeline joint venture final investment decision.
Outlook is supported by robust cash flow, a $10 billion project backlog, and growing LNG demand, but risks include high debt levels and execution challenges. Analysts are mixed with 47% buy ratings. The stock offers a dividend yield near 3.7%, appealing for income-focused investors amid stable fee-based operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
